Charles River Laboratories International, Inc. (CRL) Given a $117.00 Price Target at Robert W. Baird

Robert W. Baird set a $117.00 price objective on Charles River Laboratories International, Inc. (NYSE:CRL) in a research report report published on Monday. The brokerage currently has a buy rating on the medical research company’s stock.

CRL has been the subject of several other reports. Zacks Investment Research raised Charles River Laboratories International from a hold rating to a buy rating and set a $110.00 target price for the company in a research report on Thursday, August 10th. Bank of America Corporation lowered their target price on Charles River Laboratories International from $117.00 to $115.00 and set a buy rating for the company in a research report on Friday. Jefferies Group LLC raised their target price on Charles River Laboratories International from $120.00 to $130.00 and gave the stock a buy rating in a research report on Monday, October 9th. Royal Bank Of Canada assumed coverage on Charles River Laboratories International in a research report on Tuesday, September 19th. They set a sector perform rating and a $110.00 target price for the company. Finally, BidaskClub raised Charles River Laboratories International from a buy rating to a strong-buy rating in a research report on Tuesday, August 22nd. Seven investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. The company has an average rating of Buy and a consensus target price of $106.05.

Shares of Charles River Laboratories International (NYSE CRL) traded down $0.19 during trading hours on Monday, reaching $101.93. The company had a trading volume of 640,200 shares, compared to its average volume of 381,315. The company has a market cap of $4,836.56, a price-to-earnings ratio of 20.06, a P/E/G ratio of 1.63 and a beta of 0.94. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.62 and a current ratio of 1.88. Charles River Laboratories International has a twelve month low of $69.51 and a twelve month high of $119.05.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Thursday, November 9th. The medical research company reported $1.30 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.22 by $0.08. The business had revenue of $464.23 million during the quarter, compared to analyst estimates of $458.93 million. Charles River Laboratories International had a return on equity of 26.58% and a net margin of 10.72%. Charles River Laboratories International’s revenue for the quarter was up 9.0% compared to the same quarter last year. During the same period last year, the company earned $1.18 EPS. equities analysts anticipate that Charles River Laboratories International will post 5.12 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by Stock Observer and is owned by of Stock Observer. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://www.thestockobserver.com/2017/11/14/charles-river-laboratories-international-inc-crl-given-a-117-00-price-target-at-robert-w-baird.html.

In related news, insider Davide Molho sold 5,982 shares of the business’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $107.55, for a total value of $643,364.10. Following the completion of the sale, the insider now directly owns 22,714 shares of the company’s stock, valued at approximately $2,442,890.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider William D. Barbo sold 4,000 shares of the business’s stock in a transaction dated Thursday, August 17th. The shares were sold at an average price of $99.91, for a total value of $399,640.00. Following the completion of the sale, the insider now directly owns 20,424 shares of the company’s stock, valued at $2,040,561.84. The disclosure for this sale can be found here. Over the last three months, insiders bought 10,500 shares of company stock valued at $2,885 and sold 1,016,147 shares valued at $1,991,154. Company insiders own 2.20% of the company’s stock.

Institutional investors have recently modified their holdings of the stock. YorkBridge Wealth Partners LLC increased its position in Charles River Laboratories International by 445.5% in the 3rd quarter. YorkBridge Wealth Partners LLC now owns 1,091 shares of the medical research company’s stock valued at $118,000 after buying an additional 891 shares in the last quarter. Advisor Group Inc. increased its position in Charles River Laboratories International by 159.4% in the 3rd quarter. Advisor Group Inc. now owns 1,538 shares of the medical research company’s stock valued at $165,000 after buying an additional 945 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Charles River Laboratories International by 12.7% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the medical research company’s stock valued at $181,000 after buying an additional 202 shares in the last quarter. Riverhead Capital Management LLC increased its position in Charles River Laboratories International by 14.7% in the 2nd quarter. Riverhead Capital Management LLC now owns 1,931 shares of the medical research company’s stock valued at $195,000 after buying an additional 247 shares in the last quarter. Finally, Cambridge Advisors Inc. bought a new stake in Charles River Laboratories International in the 2nd quarter valued at about $202,000. 97.46% of the stock is owned by institutional investors and hedge funds.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Analyst Recommendations for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply